Oncolytics Biotech (ONCY) EBITDA (2009 - 2025)

Oncolytics Biotech (ONCY) has 17 years of EBITDA data on file, last reported at -$10.6 million in Q3 2025.

• On a quarterly basis, EBITDA fell 52.71% year-over-year to -$10.6 million in Q3 2025; TTM through Sep 2025 was -$28.1 million, a 269.93% decrease from a year earlier, with the FY2025 full-year figure at -$28.7 million, down 12.42% from the prior year.
• EBITDA for Q3 2025 stood at -$10.6 million, down from -$4.8 million in the prior quarter.
• Over the last five years, EBITDA for ONCY reached as high as $7.4 million in Q3 2023 and fell as low as -$35.6 million in Q4 2021.
• Historically, EBITDA has averaged -$6.2 million across 5 years, with a median of -$5.1 million in 2021.
• On a YoY basis, EBITDA climbed as much as 333.77% in 2023 and fell as far as 241.73% in 2023.
• Year by year, EBITDA stood at -$35.6 million in 2021, then advanced by 15.42% to -$30.1 million in 2022, then surged by 90.66% to -$2.8 million in 2023, then tumbled by 102.55% to -$5.7 million in 2024, then tumbled by 86.56% to -$10.6 million in 2025.
• Per Business Quant data, the three most recent EBITDA figures were -$10.6 million in Q3 2025, -$4.8 million in Q2 2025, and -$5.7 million in Q4 2024.